Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Hot Sheets Newsletter: 2018

Hot SHEET 2018

Made possible by charitable contributions from


 – Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Yearly Biopsy Not Needed for Prostate Cancer Surveillance
  • When PSA Is 4-10 ng/mL, phi Test Helps with Biopsy Decision
  • Cancer Survivors & PTSD
  • Phase 1 Trial of ProscaVax Vaccine Stopped PCa Progression
  • Amiloride for Managing Abiraterone-Induced Mineralocorticoid Excess
  • Doc Moyad’s No Bogus Science: "Low-Calorie Diet & Weight Loss"
  • Index of Medical Articles Published in the 2017 Us TOO Hot SHEET
  • Doctor Chodak’s Bottom Line
  • Existing Parasite Drug May Fight 8 Prostate and Colon Cancers
  • Enzalutamide Safe in Seizure-Prone Prostate Cancer Patients
  • Repeat Prostate Biopsies Do Not Raise Risk of Post-RP Complications
  • Metastasis-Directed Treatment Improves Progression-Free Survival
  • New Prostate Cancer Imaging Tracer
  • Doc Moyad’s No Bogus Science: “Exercise and the Risk of Dementia?”
  • Shorter but Higher Dose of RT Cuts Risk of Prostate Cancer Recurrence
  • Circulating Tumor Cell Count Predicts Overall Survival in Prostate Cancer
  • NCCN: Favorable vs. Unfavorable Intermediate-Risk Prostate Cancer
  • Safety Concerns with Trial of Xofigo/Zytiga Combination
  • Contemporary Incidence and Outcome of Lymph Node Metastases
  • Smaller Difference in PCa Death Risk Found Between RP & RT
  • Doctor Chodak’s Bottom Line
  • Focal Therapy for Primary Localized PCa Remains Investigational
  • Did They Die of Prostate Cancer?
  • Low PSA on ADT is Still Prognostic in New Treatment Era
  • Sildenafil for Penile Rehabilitation
  • Long-Term Antitumor Activity and Safety of Enzalutamide
  • Doc Moyad’s No Bogus Science: “Flu/Shingles Vaccine & Heart Attack?”
  • Physician Trust Tied to PSA Testing
  • Obese Men Have a Higher Risk of Post-RP Biochemical Recurrence
  • The Role of Lymph Node Dissection for Patients with Prostate Cancer
  • Routine Office Urine Culture Before Prostate Biopsy is Unnecessary
  • Doctor Chodak’s Bottom Line
  • Brachytherapy Boost Tops Surgery for Prostate Cancer
  • Single PSA Test Fails to Reduce Prostate Cancer Deaths
  • Imaging Agent Can Change Plans for Recurrent Prostate Cancer
  • No Definitive Link Between Physical Activity and Prostate Cancer
  • Novel PET Imaging Agent Detects Prostate Cancer Recurrence Early
  • Doc Moyad’s No Bogus Science: “Low-Fat vs. Low-Carb & Your Wallet?!”
  • Current PSA Monitoring Ignores Risk to Some Prostate Cancer Survivors
  • Liquid Biopsies Measuring Circulation Tumor DNA Not Ready for Prime Time
  • Hyperbaric Oxygenation Therapy to Preserve Post-RP Erectile Function
  • Doctor Chodak’s Bottom Line
  • Inclusion Criteria for Prostate Cancer Trials Inadvertently Exclude Blacks
  • Brachytherapy vs. Radical Prostatec-tomy in High-Risk Localized PCa
  • Higher Resource Use in mCRPC Patients Does Not Benefit Outcomes
  • FDA Approves Apalutamide for Non-metastatic Castrate-Resistant PCa
  • Higher RT Dose May Not Improve Prostate Cancer Outcomes
  • Digital Rectal Examination for Prostate Cancer Screening
  • Doc Moyad's No Bogus Science: – "Curcumin is Having a Good 2018?!"
  • QOL with Chemohormonal Treatment in Prostate Cancer
  • More High-Risk Prostate Cancer Now in the US Than Before
  • After Cancer, Accelerated Aging?
  • Diet, Exercise with Behavioral Counseling Can Reduce ADT Side Effects
  • Doctor Chodak’s Bottom Line
  • Nerve-Sparing Prostatectomy Does Not Benefit Everyone
  • USPSTF: Prostate Cancer Screen-ing Should be an Individual Decision
  • EBRT with Brachytherapy Matches Surgery for Prostate Cancer
  • Ultrahypofractionated RT for Prostate Cancer is Safe and Effective
  • Long-Term Outcomes of Adjuvant Treatment in High-Risk PCa
  • Doc Moyad’s No Bogus Science: “The Ripple Effect?!”
  • 4+3 vs. 3+4 PCa and Risk of Metastatic Disease at Time of Diagnosis
  • Predictors of Adverse Pathology After Radical Prostatectomy
  • PCa & Lung Cancers May Be #1 in HIV+ Subjects by Year 2030
  • Men Much Less Likely Than Women to Get BRCA Testing, Despite Risks
  • Doctor Chodak’s Bottom Line
  • No Survival Bump for Localized PCa with More Frequent PSA Tests
  • Notable Differences with Three Prostate Cancer Genomic Tests
  • Black Men Do Well in Prostate Cancer Trials
  • IsoPSA Test Could Reduce Overdiagnosis/Overtreatment in PCa
  • Laser Focal Ablation of Prostate Cancer Improves Outcomes
  • Doc Moyad’s No Bogus Science:- “Eight Glasses of Water Per Day?!”
  • No Immediate Treatment for Low-Risk Prostate Cancer
  • Prostate Cancer Survival Odds Worse for Smokers
  • This “Metastasis-Blocking” Compound Could Stop the Spread of Cancer
  • Abiraterone May Be More Effective in Black Men with Advanced PCa
  • Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
  • Doctor Chodak’s Bottom Line
  • Prostvac-V/F Vaccine Found Not to Improve Survival 
  • DNA Test Identified Men with Six-Fold Increased Risk of Prostate Cancer 
  • Enzalutamide Postpones Metastasis for a Subset of High-Risk PCa Patients 
  • Phase III Trial Between Adjuvant Docetaxel and Surveillance 
  • Statin Use and Time to Progression in Men on Active Surveillance for PCa 
  • Doc Moyad’s No Bogus Science: “The Final Verdict on Coffee is… You?! 
  • Novel Assay Can Guide Therapy in Advanced Prostate Cancer 
  • Metformin Added to ADT for Prostate Cancer Ups Survival 
  • Complications from Prostate Biopsy Deter Men from Re-Biopsy 
  • CDK12 Variants and Vulnerability to Immune Checkpoint Inhibitors 
  • Finasteride Safely Prevents PCa 
  • Androgen Deprivation Therapy is Associated With Prolongation of QTc Interval in Men with Prostate Cancer 
  • Doctor Chodak’s Bottom Line 
  • Shorter ADT Course May Suffice for High-Risk Prostate Cancer
  • Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
  • No Benefit of Adding Abiraterone to Enzalutamide in Metastatic CRPC
  • Cost Effectiveness of SelectMDx in Prostate Cancer Risk Assessment
  • Proton Therapy Trials “At Risk,” Slow to Enroll Patients
  • Doc Moyad's No Bogus Science: "Artificially Sweetened Beverages…"
  • Aggressive Prostate Cancer Type is "Fairly Prevalent"
  • Androgen Deprivation Therapy Ups Risk of a Thromboembolic Event
  • MRI-Targeted Biopsies May Have a Role in Active Surveillance
  • Large US Study Targets Prostate Cancer in Black Men
  • Doctor Chodak's Bottom Line
  • Prostate cancer Screening Has No Effect on Overall Mortality 
  • LDR Brachytherapy Beneficial in High-Risk Prostate Cancer 
  • Nuclear Pore Proteins May Be Effective Anticancer Targets for PCa 
  • PSA Testing Initiation and Shared Decision-Making 
  • Clinical Utility of Total Length Gleason Pattern 4 on Biopsy 
  • Doc Moyad’s No Bogus Science: “No Safe Level of Alcohol?! What!?! 
  • Men's Eating and Living (MEAL) Study (CALGB 70807 Alliance) 
  • Long-Term Outcomes After Deferred RP with Initial AS Treatment 
  • Impact of Family History of Cancer on Risk and Mortality of Second Cancers 
  • Experts Find Flaw in Prostate Cancer PET Imaging Technique 
  • Prostate Cancer Radiotherapy Effective Long-Term 
  • Obese Prostate Cancer Patients Do Worse After RP 
  • SBRT Appears Effective for Oligometastatic Prostate Cancer 
  • Test Panel Shows 94% Accuracy in Detecting Aggressive PCa 
  • Doctor Chodak’s Bottom Line
  • PCa Detection in Men 70 and Older Cost Medicare $1.2B Every 3 Years 
  • Dismissing Reduced Abiraterone Dose is Absolutely Wrong 
  • Can Aspirin Help Treat Cancer?
  • Simple Clinical Factors May Aid Prognosis in Non-Metastatic CRPC 
  • Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer 
  • Doc Moyad’s No Bogus Science: “Low-Dose Aspirin Dangerous? Yup!” 
  • Apalutamide Treatment In Metastatic Castration-Resistant Prostate Cancer 
  • Immunotherapy Could Offer Hope for Men with Aggressive Prostate Cancers 
  • Surgery and Radiation for Advanced Prostate Cancer Offers Better Survival 
  • High Mutation Load Seen in the High- Risk Prostate Tumors of African Men 
  • Doctor Chodak’s Bottom Line
  • Study Private Payer Coverage of Prostate MRI Lagging 
  • Adding Radium-223 to Abiraterone No Help in Prostate Cancer
  • New Data on RT in Prostate Cancer Are “Practice Changing”
  • ADT plus Pelvic Node RT & Freedom from Prostate Cancer Progression
  • Better Outcomes with RT for Black Prostate Cancer Patients
  • Doc Moyad’s No Bogus Science: “VITAL = the End of the Vitamin D Debate? Nope!!”
  • CyberKnife® SBRT Results From 38 Institutions in More than 500 Men Followed Over Seven Years
  • Agent Orange Exposure Does Not Appear to Worsen Prostate Cancer Outcomes
  • Doctor Chodak’s Bottom Line



More Resources